Managing the Pre- and Post-analytical Phases of the Total Testing Process by Hawkins, Robert
Hawkins R
Managing the extra-analytical phase
5 http://dx.doi.org/10.3343/alm.2012.32.1.5 www.annlabmed.org
Ann Lab Med 2012;32:5-16
http://dx.doi.org/10.3343/alm.2012.32.1.5
Review article
Clinical Chemistry
ISSN 2234-3806 • eISSN 2234-3814 
Managing the Pre- and Post-analytical Phases of the 
Total Testing Process
Robert Hawkins, M.D.
Department of Laboratory Medicine, Tan Tock Seng Hospital, Tan Tok Seng, Singapore
For many years, the clinical laboratory’s focus on analytical quality has resulted in an error 
rate of 4-5 sigma, which surpasses most other areas in healthcare. However, greater ap-
preciation of the prevalence of errors in the pre- and post-analytical phases and their po-
tential for patient harm has led to increasing requirements for laboratories to take greater 
responsibility for activities outside their immediate control. Accreditation bodies such as 
the Joint Commission International (JCI) and the College of American Pathologists (CAP) 
now require clear and effective procedures for patient/sample identification and commu-
nication of critical results. There are a variety of free on-line resources available to aid in 
managing the extra-analytical phase and the recent publication of quality indicators and 
proposed performance levels by the International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) working group on laboratory errors and patient safety provides 
particularly useful benchmarking data. Managing the extra-laboratory phase of the total 
testing cycle is the next challenge for laboratory medicine. By building on its existing qual-
ity management expertise, quantitative scientific background and familiarity with informa-
tion technology, the clinical laboratory is well suited to play a greater role in reducing errors 
and improving patient safety outside the confines of the laboratory.
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INTRODUCTION
In recent years, there has been increasing interest in quality im-
provement and patient safety activities in healthcare. The clinical 
laboratory has a leader in the field of healthcare quality manage-
ment with a focus on analytical quality born of its scientific back-
ground and was one of the first areas to use quantitative statisti-
cal control methods. However laboratories are now being asked 
to widen their focus to consider activities outside their immediate 
control. Accreditation agencies are increasingly requiring labora-
tories to go beyond analytical quality and take responsibility for 
the pre- and post-analytical (or extra-analytical) phases where 
most errors arise. These new challenges are a change from the 
traditional laboratory-based activities with which many laboratory 
staff is comfortable and this new role can cause some unease 
and discomfort. This article outlines the different phases of the 
total testing process, discusses laboratory accreditation require-
ments for the extra-analytical phase and describes some of the 
resources available for laboratories in managing this unfamiliar 
area.
1. The total testing process (TTP)
The total testing process (or total testing cycle) is based on the 
original brain-to-brain loop concept described by Lundberg [1, 
2]. He outlined a series of activities, starting with the clinical 
question in the clinician’s mind, leading to test selection, sample 
collection, transport to the laboratory, analysis, reporting back to 
the clinician, and final interpretation and decision making by the Hawkins R
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clinician. These activities have traditionally been separated into 
three phases (pre-analytical, analytical and post-analytical). 
Some authors have introduced the “pre-pre-” and “post-post-” 
analytical phases to identify activities associated with the initial 
selection of tests and with the interpretation by clinicians re-
spectively, to differentiate them for the pure collection/transport 
activities (pre-analytical phase) and reporting (post-analytical 
phase) [3, 4]. There is some evidence that these steps are more 
error-prone than other pre- and post-analytical activities [3-8]. 
However, the definition and use of such terms is not universal. 
Indeed the definition of even basic terms such as pre-analytical, 
analytical and post-analytical can vary between authorities. 
2. Errors in the total testing phase
Healthcare is a relatively high risk area and the overall defect 
rate in healthcare in the United States is estimated to be 31-
69% [9]. Error rates are often described using the sigma con-
cept, which refers to the number of standard deviations that lie 
between the process mean and the specification limit. As the 
process standard deviation becomes smaller, more standard 
deviations will fit between the mean and the specification limit, 
increasing the sigma number and decreasing the likelihood of 
items exceeding the specification limit. Using this measure, 
healthcare performs at a 1-2 sigma level, which compares poorly 
with non-healthcare industries such as airline baggage handling 
(approximately 4 sigma) [9]. Performance varies in different ar-
eas of healthcare, with values of 1 sigma (e.g., use of beta-block-
ers post myocardial infarction, detection and management of 
depression) to 3 sigma (e.g., adverse drug events, hospital-ac-
quired infections). Higher error rates can be expected in institu-
tions under pressure to increase revenue, lower costs and oper-
ate close to or over full capacity [10]. 
  The analytical phase of laboratory medicine is arguably the 
best performing sector in healthcare with close to 5 sigma per-
formance (0.002%) [9, 11]. This is more than 3,000 times lower 
than the rates of infection and medication errors and reflects 
the standardised quantitative nature of much of laboratory med-
icine testing, which is well suited to statistical quality control 
measures [12]. However, the accomplishments of laboratory 
medicine drop when errors in all phases of the total testing pro-
cess are considered [13, 14]. The proportion of errors associ-
ated with the two extra-analytical phases is 4-5 times that seen 
in the analytical phase, with the pre-analytical phase consistently 
representing over half of all errors in published studies [12, 15-
19]. In a representative study, an Italian stat laboratory used the 
same methodology to assess error rates in 1996 and 2006 and 
found that, despite a 34% reduction in error rate, the pattern of 
62% pre-analytical, 15% analytical and 23% post-analytical 
phase errors remained basically unchanged [20]. Given the high 
volumes of laboratory tests performed globally, even a low prev-
alence of errors translates into significant absolute numbers of 
occurrences and opportunities for adverse patient outcome. Al-
though some laboratories have developed mechanisms to de-
tect errors and improve pre- and post-analytical quality, there 
remains significant room for improvement in the quality of the 
extra-analytical testing phase [21-23]. 
  The commonest causes of errors in the total testing process 
as compiled by Plebani are shown below [22].
1) Pre-pre-analytical (46-68%)
Inappropriate test request, order entry, patient/specimen mis-
identification, sample collected from infusion route, sample col-
lection (hemolysis, clotting, insufficient volume, etc.), inappro-
priate container, handling, storage and transportation.
2) Pre-analytical (3-5%)
Sorting and routing, pour-off, aliquoting, pipetting and labeling, 
centrifugation (time and/or speed).
3) Analytical (7-13%)
Equipment malfunction, sample mix-ups, interference (endoge-
nous or exogenous), undetected failure in quality control.
4) Post-analytical (13-20%)
Erroneous validation of analytical data, failure in reporting/ad-
dressing the report, excessive turn-around-time, improper data 
entry and manual transcription error, failure/delay in reporting 
critical values.
5) Post-post-analytical (25-46%)
Delayed/missed reaction to laboratory reporting, incorrect inter-
pretation, inappropriate/inadequate follow-up plan, failure to or-
der appropriate consultation.
  These lists illustrate the use of the pre-pre- and post-post-an-
alytical categories - note, for example, that Plebani includes 
choice of container, collection, handling and transportation as 
pre-pre-analytical activities, resulting in most errors being cate-
gorised as pre-pre-analytical rather than pre-analytical. The lack 
of standardisation in such taxonomy accounts for some of the 
variation seen in reported error rates and can complicate dis-
cussions [24]. However, the concepts may have value in shap-Hawkins R
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ing the laboratory’s approach to error management by acting as 
an explicit reminder of the error-prone nature of test selection 
and interpretation activities [25]. 
  Errors in healthcare are of concern when they lead to actual 
or potential adverse outcomes for patients. Given the complex 
nature of healthcare and the difficulty in assessing the effect of 
a specific laboratory error on patient management, the preva-
lence of proven patient harm is difficult to assess. Obvious ex-
treme errors in qualitative results with clear links to therapy or 
management decisions (e.g., histopathology, blood transfusion, 
microbiology, virology, genetic testing) are easiest to measure 
but assessing the effect of quantitative errors in clinical biochem-
istry and haematology results is much more difficult. Such diffi-
culties mean that present measurements probably significantly 
underestimate the size of the problem in light of the high vol-
ume of quantitative testing performed in clinical laboratories. A 
review of the available literature on laboratory errors found great 
heterogeneity in the studies where the data collection method 
appeared to be the strongest influence on error prevalence and 
type [19]. Published data suggest that 24-30% of laboratory er-
rors have an effect on patient care while actual or potential pa-
tient harm occurs in 3-12% [20, 22, 26]. Some areas, such as 
molecular genetics testing, can have actual harm rates of up to 
100% [19, 27]. A recent study illustrating the dichotomy between 
the large potential for harm but the much smaller rate of actual 
harm describes a five-point scoring system for actual and po-
tential adverse impact score elements [28, 29]. Errors were clas-
sified as pre-analytical (88.9%), analytical (9.6%) and post-ana-
lytical (1.5%). Classification and grading of quality failures in the 
clinical biochemistry laboratory showed that 72.7% of errors had 
an actual adverse impact score of 1 (least severe grade) while 
65.9% of errors had a potential adverse impact score of 5 (most 
severe grade) [28]. 
  Although the importance of the pre- and post-analytical phase 
has been acknowledged for many years, laboratories have often 
overlooked this area in their quality management programmes, 
focussing instead on analytical quality and associated activities 
within their direct control. The main reason for this neglect has 
been governance issues due to the variety of the different physi-
cal locations and staff groups (laboratory staff, clinicians, phle-
botomists, porters) involved in the total testing process. Igno-
rance by non-laboratory staff of the importance of the extra-ana-
lytical phase, difficulties in capturing appropriate monitoring 
data, taxonomical issues in defining and classifying errors and 
narrow interpretations of the laboratory’s role have all contrib-
uted to this inaction. The variety of different terms used to de-
fine errors, including mistakes, blunders, defects, outliers, un-
acceptable results, quality failures, have not helped discussion 
[22]. The term “laboratory error” is defined in International Or-
ganization for Standardization (ISO) 22367 as “failure of planned 
action to be completed as intended, or use a wrong plan to 
achieve an aim, occurring at any part of the laboratory cycle, 
from ordering examinations to reporting results and appropri-
ately interpreting and reacting to them” and is the preferred 
term [22, 30]. A more recent and perhaps more useful descrip-
tion of laboratory error is “any defect from ordering tests to re-
porting results and appropriately interpreting and reacting on 
these” [31]. Recent changes to accreditation requirements are 
forcing laboratories to pay attention to this area. 
3. Accreditation requirements for the extra-analytical phase
The present interest in patient safety initiatives can be traced to 
studies in the 1990s showing that up to 4% of patients in the 
United States suffered iatrogenic injuries, of which two-thirds 
were mistakes [32, 33]. Even higher rates were noted in Austra-
lia (13%) and the UK (10%) [34, 35]. A series of publications in 
the US and UK between 1999 and 2004 subsequently led to 
greater requirements for active management of the extra-analyt-
ical phase of the total testing process [36-39]. The Institute of 
Medicine reports “To Err is Human: Building a Safer Health Sys-
tem” (1999) and “Crossing the Quality Chasm: a New Health 
System for the 21st Century” (2001) described the high rates of 
medical error in hospitals in the United States and outlined 
strategies to reduce their incidence. While the first report high-
lighted the many American patients who die each year from 
medical errors, the second described six aims for patient care, 
specifically safeness, effectiveness, efficiency, equitability, pa-
tient-centeredness, timeliness, and rules for care delivery rede-
sign. Medical errors were defined as the failure of a planned ac-
tion to be completed as intended or the use of a wrong plan to 
achieve an aim. The majority of medical errors was not the re-
sult of individual recklessness or the actions of a particular group 
but was caused by faulty systems, processes, and conditions 
that led people to make mistakes or fail to prevent them. Amongst 
the strategies proposed were the raising of performance stan-
dards and expectations for improvements in safety through the 
actions of oversight organizations and professional groups and 
the implementing of safety systems in healthcare organizations 
to ensure safe practices at the delivery level. 
  These recommendations have been translated in new specific 
requirements to enhance patient safety by US-based accredita-
tion bodies with similar provisions in other international stan-Hawkins R
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dards. They can also be found in voluntary guidelines such as 
those of the National Quality Forum whose 2009 publication “Pre-
ferred Practices for Measuring and Reporting Patient Safety and 
Communication in Laboratory Medicine” focuses on the same 
areas of patient/sample identification, sample acceptability, test 
order accuracy, verbal communication and critical result report-
ing targeted by the accreditation bodies described below [40]. 
1) Joint Commission International
The Joint Commission International (JCI) is a subsidiary of The 
Joint Commission (TJC), formerly the Joint Commission on Ac-
creditation of Healthcare Organizations (JCAHO). TJC is a United 
States-based not-for-profit organization that accredits over 19,000 
healthcare organizations and programs in the United States while 
JCI accredits healthcare organizations in over 80 countries. On-
site inspections follow a three cycle. JCI requires all accredited 
organizations to implement the JCI International Patient Safety 
Goals (IPSGs) under the International Standards for Hospitals 
[41]. The purpose of the IPSGs is to promote specific improve-
ments in patient safety. There are six goals, of which the first 
two specifically refer to the extra-analytical phase of the total 
testing process. 
  The first Standard IPSG 1 requires the organization to develop 
an approach to improve accuracy of patient identification and 
applies to the pre-analytical phase of the total testing process. 
Of all the pre-analytical processes, sample collection is arguably 
the most critical [42, 43]. Identification errors can result in inap-
propriate treatment and mislabeling of blood specimens may 
result in hemolytic transfusion reactions from incompatible 
blood [44, 45]. Up to 50% of transfusion-related deaths result 
from identification error [46-49]. Up to 1 in 18 identification er-
rors can result in an adverse patient outcome [50]. Identification 
errors are particularly common amongst inpatient samples [51]. 
Identification processes when giving blood, or blood products or 
taking blood and other specimens for clinical testing are specifi-
cally highlighted by JCI. Patients must be identified using at 
least two ways, such as name, identification number, birth date 
or bar-coded wristband. The patient’s room number or location 
cannot be used for identification purposes. Evidence of imple-
mentation of this system for blood and blood product adminis-
tration and clinical sample collection are amongst the measur-
able elements for this goal.
  IPSG 2 requires the organization to develop an approach to 
improve the effectiveness of communication among caregivers 
and applies to both the pre- and post-analytical phases of the 
total testing process. Verbal and telephone requests (pre-analyt-
ical phase) and the reporting back of critical test results (post-
analytical phase) are specifically mentioned as areas for action. 
Critical values are defined as those which represent potentially 
life-threatening situations and in which reporting delays can re-
sult in serious adverse patient outcomes [52-57]. Policies or 
procedures are required for verbal and telephone orders that in-
cludes the writing down (or entering into a computer) of the 
complete order or test result by the receiver of the information; 
the reading back of the order or test result; and confirmation 
that what has been written down and read back is accurate. Al-
though not all laboratories accept verbal or telephone requests, 
all will report critical results and thus need to comply with this 
requirement. Evidence of writing down, reading back and con-
firmation of verbal/telephone requests and critical results are 
the measurable elements for this standard.
  The importance of pre-analytical processes and critical result 
communication are reiterated in AOP (Assessment of Patients) 
standard 5.6, requiring procedures for test ordering and sample 
collection, identification, transport, storage, preservation, receipt 
and tracking, and AOP 5.3.1, which requires a collaborative 
method to be used to develop processes for reporting of critical 
results, respectively [58]. 
2)     College of American Pathologists Laboratory Accreditation Pro-
gram
The College of American Pathologists (CAP) Laboratory Accredi-
tation Program is an international program designed to improve 
patient safety by advancing the quality of pathology and labora-
tory services through education, standard setting, and ensuring 
laboratories meet or exceed regulatory requirements. More than 
6,000 laboratories worldwide are CAP accredited. Inspections 
are carried out by teams of practicing laboratory professionals 
using checklists which cover general laboratory functions as 
well as specific disciplines. The checklist questions are explicit 
in their intent and the required evidence of compliance (e.g., 
records, written procedures and policies).
  The Laboratory General Checklist specifically refers to the 
monitoring of extra-analytical quality and the CAP laboratory pa-
tient safety goals [59]. Item GEN.20316 requires the quality man-
agement program to include monitoring key indicators of quality. 
Pre-analytical examples given include patient/specimen identifi-
cation (e.g., percent of patient wristbands with errors, percent of 
ordered tests with patient identification errors, or percent of re-
sults with identification errors), test order accuracy (e.g., per-
cent of test orders correctly entered into a laboratory computer), 
specimen acceptability (e.g., percent of general hematology Hawkins R
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and/or chemistry specimens accepted for testing), surgical pa-
thology/cytology specimen labeling (e.g., percent of requisitions 
or specimen containers with one or more errors of pre-defined 
type), and blood culture contamination (e.g., percent of blood 
cultures that grow bacteria that are highly likely to represent 
contaminants). Post-analytical examples given include critical 
value reporting (e.g., percent of critical results with documenta-
tion that results have been reported to caregivers, percent of 
critical results for which the primary clinician cannot be con-
tacted in a reasonable period of time) and stat test turnaround 
time (either collection-to-reporting turnaround time or receipt-
in-laboratory-to-reporting turnaround time of tests ordered with 
a stat priority). Turnaround time potentially encompasses all 
three phases of the total testing process and can be an excel-
lent single measure of laboratory performance. 
  Items GEN.20348 and GEN.20364 deal with monitoring of pre-
analytical and post-analytical processes, respectively, and again 
list examples of pre-analytical (accuracy of transmission of phy-
sicians’ orders, specimen transport and preparation, requisition 
accuracy, quality of phlebotomy services, specimen acceptabil-
ity rates) and post-analytical measures (accuracy of data trans-
mission across electronic interfaces, reflex testing, turnaround 
time from test completion to reporting and interpretability of re-
ports) measures. A written quality management plan listing the 
processes to be monitored and defining the criteria used to 
monitor these processes as well as records of monitoring data 
with review and comparison to benchmark data/defined thresh-
olds is required.
  Item GEN.20365 requires the laboratory to specifically address 
the four CAP Laboratory Patient Safety Goals, all of which refer 
to the extra-analytical phases. The first two match JCI IPSGs 1 
and 2. The first goal requires the laboratory to improve patient 
and sample identification at specimen collection, analysis and 
result while the second refers to improvement of verification and 
communication of life-threatening or life-altering information re-
garding malignancies, HIV (and other serious infectious dis-
eases), cytogenetic abnormalities, and critical results. In line 
with the emphasis on patient safety and a holistic multidisci-
plinary approach to quality management, the third goal is to im-
prove identification, communication and correction of errors in 
a timely manner while the fourth is to improve the coordination 
of the laboratory’s patient safety role within healthcare organiza-
tions (nursing, administration, point-of-care personnel and pro-
viders). Again records of evaluation or monitoring of processes 
related to each of the patient safety goals are required.
Other items in both the Laboratory General and discipline-spe-
cific checklists refer to pre- and post-analytical processes. For 
example, GEN.40490 requires the individual collecting a speci-
men to positively identify the patient prior to specimen collection 
using at least 2 identifiers. GEN.40491 requires primary speci-
men containers to be labeled with at least 2 identifiers. GEN. 
40535 and 40540 require quality management system for prob-
lems in specimen transport, including from remote sites and 
those not under the control of the laboratory. GEN.41320, 41330 
and 41340 reinforce the procedures and monitoring of critical 
result handling with similar requirements restated in the disci-
pline-specific checklists (e.g., CHM.15100 and 15200 in the 
Chemistry and Toxicology checklist). 
3)     ISO 15189: 2007 Medical laboratories - Particular requirements 
for quality and competence
The ISO 15189:2007 standard is designed for use by medical 
laboratories in developing their quality management systems and 
assessing their own competence, and for use by accreditation 
bodies in confirming or recognising the competence of medical 
laboratories [60]. 
  Although ISO 15189:2007 covers all three phases of the total 
testing process, it is less prescriptive and explicit in managing 
and monitoring of extra-analytical quality issues compared to 
the JCI and CAP standards. For example, section 4.2.2 on the 
quality management (QM) system states that “the QM system 
shall include, but not be limited to, internal quality control and 
participation in organised inter-laboratory comparisons such as 
external quality assessment schemes”. A list of 23 items for in-
clusion in the quality manual mentions transportation, collec-
tion, handling of samples, reporting of results and communica-
tions and other interaction with patients, health professionals, 
referral laboratories and suppliers in passing (item 4.2.4) while 
the monitoring programme describes calibration and function of 
instruments, reagents and analytical system (item 4.2.5). Moni-
toring of turnaround time as part of the management review is 
required (item 4.15.2 k) as is monitoring of the transportation of 
samples to the laboratory with respect to time frame, tempera-
ture, preservatives and safety (item 5.4.6). “External quality as-
sessment programmes should, as far as possible, … have the 
effect of checking the entire examination process, including pre- 
and post-examination procedures” (item 5.6.4). Procedures and 
records of critical result handling are required (items 5.8.7 and 
5.8.10) and the definition of critical results should be decided 
locally in agreement with the clinicians using the laboratory 
(item 5.8.8). This provides an opportunity to both customize 
critical value reporting to clinician needs and educate physi-Hawkins R
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cians in the concept of critical values [61].
  The increasing recognition of the importance of the extra-ana-
lytical phases in laboratory medicine is seen not only in accredi-
tation standards from outside authorities but also in the recent 
deliberations of laboratory quality experts. In May 2010, a meet-
ing of over 40 medical laboratory opinion leaders met to discuss 
issues and current challenges for laboratory medicine [62]. One 
working group looked at assessment of risk and control of sources 
of error in the laboratory path of workflow. They considered two 
recently published CLSI risk management guidelines relevant to 
extra-analytical quality concerns and examined two specific 
questions in this area [63, 64]. The first question was “What fac-
tors, activities or conditions in the total testing process contrib-
ute to risk of harm to the patient?” Using the CLSI document on 
management of non-conforming laboratory events, the group 
identified the following activities: ordering the test, sample col-
lection, sample labeling/patient identification, sample transport, 
sample accession/handling processing, and sample quality 
(pre-analytical phase); and result interpretation (including cal-
culation errors), data entry, and transmission and communica-
tion of results (post-analytical phase) [65]. It was felt that the 
most problematic area in risk management is tackling the hu-
man factor in the process. The second question was “Because 
even one bad result issued by a virology laboratory or blood 
bank may compromise both patient health and laboratory credi-
bility, how should labs manage risk in these laboratories? Are 
there any specific special precautions?” Responses included 
the need to gain cooperation from all stakeholders, to standard-
ize and simplify processes, to use technology wherever possible, 
to validate the steps in the TTP and continually monitor activities 
in the TTP to implement quality improvement.
  Both the laboratory quality experts and the accreditation au-
thorities recognize that laboratory medicine is a complex pro-
cess whose management requires careful integration between 
different physical sites, activities and occupational groups to 
minimize the risk of error occurrence. This is illustrated in the 
Swiss cheese model of error propagation of Reason [22, 66]. A 
system is a series of processes which can be considered analo-
gous to a stack of slices of Swiss cheese in which the holes rep-
resent opportunities for an error to pass to the next process in 
the system. Each slice is a defensive layer and can stop the er-
ror from propagating through the system. The vulnerability of 
the system is dependent on the number of defensive layers and 
their efficiency [67]. Errors can result in adverse patient out-
come when all the holes line up and the system fails to detect 
and rectify the error. For laboratory medicine, the slices repre-
sent areas such as equipment, training, supervision and quality 
assurance procedures and there is a need to close the gaps and 
strengthen the defenses to minimize the likelihood of patient 
mishap. Management strategies should recognize both the hu-
man and the system factors that can lead to errors and should 
aim for a robust integrated system which provide timely inter-
vention and correction of developing problems.
  Table 1 compares the definitions of the pre- and post-analyti-
cal processes used in CAP (items GEN.20348 and 20364) with 
the equivalent terms (pre- and post-examination procedures/
pre- and post-analytical phase) used in ISO 15189:2007 (items 
3.10 and 3.11) [59, 60]. The pre-analytical definitions are very 
similar but there are some differences in the post-analytical ar-
eas, with ISO 15189:2007 including “authorization for release” 
and “storage of samples” as post-analytical activities. These 
definitions illustrate the difficulties that can be encountered in 
discussions on extra-analytical phase errors and accounts for 
some of the variation in reported error rates. 
4.     Free resources available for managing the extra-analytical 
phase
There are a variety of free on-line resources available to the lab-
Table 1. Comparison of pre-analytical and post-analytical phase definitions [59, 60]
Phase CAP Laboratory General Checklist ISO 15189:2007
Pre-analytical  All steps in the process prior to the analytic phase of testing, starting  
with the physician’s order. Examples include accuracy of transmission of 
physicians’ orders, specimen transport and preparation, requisition 
accuracy, quality of phlebotomy services, specimen acceptability rates, etc.
Steps starting, in chronological order, from the clinicians request and 
including the examination requisition, preparation of the patient, 
collection of the primary sample, and transportation to and within the 
lab and ending when the analytical examination procedure begins.
Post - analytical All steps in the overall laboratory process between completion of the 
analytic phase of testing and results receipt by the requesting physician. 
Examples are accuracy of data transmission across electronic interfaces,
reflex testing, turnaround time from test completion to chart posting (paper 
and/or electronic), and interpretability of reports.
Processes following the examination including systematic review, 
formatting and interpretation, authorization for release, reporting and 
transmission of results and storage of samples of the examinations.
Abbreviations: CAP, College of American Pathologists; ISO, International Organization for Standardization. Hawkins R
Managing the extra-analytical phase
11 http://dx.doi.org/10.3343/alm.2012.32.1.5 www.annlabmed.org
oratory seeking background information and suggested proce-
dures for pre-analytical phase procedures. Manufacturers of 
laboratory sample containers are also a valuable source of refer-
ence and educational material which can be tailored to the spe-
cific collection and analytical equipment used by a particular 
laboratory. The following is an incomplete list of sites and publi-
cations (both commercial and non-commercial) that provides 
free information in this area. At present there is unfortunately lit-
tle on-line information on the post-analytical phase.
1) The Quality of Diagnostic Samples. This is an on-line interac-
tive version of the publication of the same name from the Work-
ing Group on Pre-analytical Quality of the German Society for 
Clinical Chemistry and Laboratory Medicine [68]. It provides 
general recommendations on sample collection as well as infor-
mation on individual analyte sample collection requirements 
and stability.
2) World Health Organisation - Use of anticoagulants in diagnos-
tic laboratory investigations 2002 [69]. Although almost a decade 
old, this document provides similar information on individual 
analyte collection requirements and stability to the “Quality of 
Diagnostic Samples” site but in a single printable document. 
3) Specimencare.com - a global pre-analytics resource centre 
[70]. This website aims to provide a single global resource of 
data and educational material on the pre-analytical phase. 
There is a wide variety of materials available, including posters, 
presentations and flowcharts.
4) Educational materials on blood sample and urine collection 
[71, 72].
5) Educational material on blood gas and capillary sample col-
lection [73].
6) Educational material on general pre-analytical quality [74].
  Until recently, there has been little available information on 
quality indicators in laboratory medicine. A review of laboratory 
quality indicators could find an evidence base for only 14 indi-
cators of which 10 were extra-analytical: test order appropriate-
ness, wristband identification errors, patient satisfaction with 
phlebotomy, specimen quality, availability of inpatient results, 
corrected laboratory reports, critical value reporting, turnaround 
time, clinician satisfaction and follow-up of abnormal cervical 
cytology [56]. Many of the indicators in common use by labora-
tories suffer from inconsistency in definition, measurement 
methodologies and reporting practices and a general lack of ba-
sic supporting evidence. Even the denominator (per patient, per 
sample, per test) used in reporting rates of errors can vary be-
tween authors [19].
  In recent years, several national and regional external quality 
assurance programmes to examine extra-analytical quality have 
been developed [75-78]. The approach with the greatest poten-
tial global utility is that of the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) Working Group on 
“Laboratory errors and patient safety” (WG-LEPS), which has 
published preliminary benchmarking data for all phases of the 
analytical phase [79-81]. The working group’s mission is to 
stimulate studies on the topic of errors in laboratory medicine, 
to collect available data and to recommend strategies and pro-
cedures to improve patient safety. One of their projects has been 
to create a systematic common reporting system for clinical lab-
oratories based on standardised data collection, and to define 
state-of-the-art and quality specifications for each quality indica-
tor independent of the size of organization and type of activities, 
complexity of processes undertaken, and different degree of 
knowledge and ability of the staff. A website is available for data 
submission (www2.csinet.it/mqiweb/) and the working group re-
cently published the results of data collected from 39 laborato-
ries (25 from Europe, 3 from USA, 3 from Asia-Pacific, 8 from 
elsewhere) from February 2008 to December 2009. 
  The quality indicators for the pre- and post-analytical phase 
together with the proposed standards are shown in Table 2. Al-
though zero defects are the ultimate goal, the quality standards 
suggested represent “state of the art” performance. In some 
cases, a single quality criterion is given due to the low value ob-
served in the study while in other, no value is given due to the 
small number of laboratories responding obtained and the wide 
range of values reported. In terms of the JCI and CAP patient 
safety goals regarding sample identification and handling of crit-
ical results, the table classifies performances of <0.4% misiden-
tified samples, <50 min average time for critical result commu-
nication, and  >96% critical result communication as meeting 
optimum levels. It should be appreciated that these are prelimi-
nary goals reflecting the heterogeneous group of laboratories 
around the world contributing to the data collection exercise. 
For laboratories that already exceed these levels, an expectation 
of even higher performance may be more appropriate. For ex-
ample, a CAP Q-Tracks study of 180 institutions showed the 
25% best performing laboratories had reported critical result 
rates of >99% in 2001, a level probably driven by US regulatory 
requirements [82]. There are differences between US and Euro-
pean practices, particularly with respect to the notifier and the 
choice of critical values [83, 84]. The laboratory’s focus on inter-
nal versus external activities also appears to vary between the 
US and the UK, with greater attention to implementation of clini-Hawkins R
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cal guidelines, test utilisation and result interpretation by physi-
cians in the UK [85]. Nevertheless these criteria represent ex-
cellent starting points for laboratories in setting benchmarks for 
extra-analytical quality monitoring and are a significant step for-
ward in developing consensus standards [86]. The group plans 
to eliminate and modify some existing indicators and develop 
new ones over the next year [81]. The project’s success depends 
on the participation and collaboration of laboratories enrolled in 
the project to help define best practice and improve performance 
and laboratories interested in participating are encouraged to 
contact the group through the website mentioned above.
  Another source of information on present practices in quality 
indicator monitoring is a recent article describing the results of a 
survey of members of the Association of Clinical Biochemists in 
the United Kingdom, which elicited responses from 335 individ-
uals [85]. The author lists 11 questions as pre-analytical, 5 as 
analytical and 7 as post-analytical, although their classification 
would not necessarily match the CAP and ISO 15189:2007 phase 
definitions discussed earlier. Most laboratories had an electronic 
handbook (84%), provided help and advice in interpreting clini-
cal laboratory data (80%) and discussed turnaround times with 
clinical staff (75%) but only 58% had a written critical limits (alert) 
list. This is a useful snapshot of quality practices in UK laborato-
ries and highlights some of the areas where improvement is re-
quired.
5. Priority areas for extra-analytical quality
Review of the accreditation criteria, patient safety concerns and 
discussions in the literature suggest some clear areas for action 
for laboratories looking to expand their quality focus outside the 
Table 2. Proposed Pre-analytical and Post-analytical Quality Specifications from IFCC Working Group Project ‘‘Laboratory Errors and Patient 
Safety’’ [81]
Performance level
Optimum Desirable Minimum Unacceptable
Pre-analytical Quality Specifications
% requests with clinical question from general practitioners/total number of requests from 
    general practitioners
>87 58-87 29-57 <29
% appropriate requests, with respect of clinical question from general practitioners /number 
    of requests that reports clinical question from general practitioners
>97 65-97 32-64 <32
% requests without physician identification/total number of requests <5 5.0-6.0 6.1-8.0 >8.0
% unintelligible requests/total number of requests <0.2 0.20-0.25 0.26-0.30 >0.30
% requests with errors concerning patient identification/total number of requests <0.4 0.40-0.50 0.51-0.60 >0.60
% requests with errors concerning physician identification/total number of requests <0.1
% requests with errors concerning input of tests (missing)/total number of requests <0.3 0.30-0.40 0.41-0.50 >0.50
% requests with errors concerning input of tests (added)/total number of requests <0.1
% requests with errors concerning input of tests (misinterpreted)/total number of requests <0.2 0.20-0.25 0.26-0.30 >0.30
% samples lost-not received/total number of samples <0.2 0.20-0.40 0.41-0.60 >0.60
% samples collected in inappropriate container/total number of samples <0.07 0.07-1.13 1.14-0.20 >0.20
% samples hemolysed (chemistry)/total number of samples <1 1.0-1.5 1.6-2.0 >2.0
% samples clotted (hematology)/total number of samples with anticoagulant <0.5 0.50-1.0 1.1-2.0 >2.1
% samples with insufficient sample volume/total number of samples <0.4 0.40-0.80 0.81-1.20 >1.20
% samples with inadequate sample-anticoagulant/total number of samples with anticoagulant <0.2 0.20-0.30 0.31-0.40 >0.40
% samples damaged in transport/total number of samples <0.1
% samples improperly labelled/total number of samples <0.07 0.07-0.15 0.16-0.20 >0.20
Post-analytical Quality Specifications
% reports delivered outside the specified time/total number of reports <0.4 0.4-0.5 0.6-0.7 >0.7
% critical values communicated/total number of critical values to communicate >96 77-96 58-76 <58
Average time to communicate critical values (min) <50 50-100 101-160 >160
Abbreviation: IFCC, International Federation of Clinical Chemistry and Laboratory Medicine.Hawkins R
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physical confines of the laboratory. The two areas of highest pri-
ority are patient/sample identification (pre-analytical quality) and 
the handling of critical results (post-analytical quality). For many 
laboratories, attention to these issues is required by regulation 
or patient safety goals and for the remainder, they are becoming 
part of the good laboratory practices expected of all laboratories 
worldwide. A variety of approaches, both procedural and infor-
mation technology-based, are now available for laboratories seek-
ing guidance [24, 83, 87].
  The next step could be to expand these items to include more 
of the testing process. In the pre-analytical area, laboratories 
can develop clear sample acceptance and rejection criteria 
which are linked to monitoring of the collection and transport 
processes. Sample haemolysis and clotting are the commonest 
causes of unsuitable blood specimens and most laboratories 
have procedures to handle such specimens at sample receipt, 
but a more pro-active approach extending back to the point of 
collection is required [26, 50, 88]. The laboratory’s procedures 
regarding unlabelled or mislabelled specimens should be clear 
and sample relabeling by laboratory personnel, clinical staff or 
third parties is strongly discouraged [67]. Collection procedure, 
container, transport temperature/time/safety and within-labora-
tory pre-analytical temperature/time/safety criteria should be 
stipulated and monitored. In the post-analytical area, attention 
to critical result reporting can be expanded to include all reports, 
ensuring that the right report goes to the right clinician within 
the right timeframe. This could include monitoring of the wider 
definition of turnaround time from test request to clinician review 
commonly used by clinicians, rather than the traditional sample 
receipt to result reporting approach favoured by many laborato-
ries [19, 89-91].
  Laboratories looking to incorporate the pre-pre- and post-post-
analytical phases into their management plans may wish to mon-
itor the appropriateness of test requesting and utility of interpre-
tative reporting. Duplicate laboratory requests repeated within 
defined intervals can represent wasted and unnecessary testing 
[92-95]. Repetition of tests can result from poor access to previ-
ous results or lack of standardisation between different laborato-
ries [96]. Given the suggestion that up to 50% of requests may 
be inappropriate, introducing strategies to manage duplicate 
testing can be a useful first step in initiating demand manage-
ment without challenging the autonomy of clinical decision mak-
ers [97]. Information technology, such as electronic medical re-
cords, clinician order entry, expert systems, electronic hand-
books and embedded hyperlinks in reports, is probably the eas-
iest way to both provide solutions and monitor performance in 
these phases [98-100]. Clinical audits and clinician satisfaction 
surveys can also be useful measures of overall laboratory effec-
tiveness [43, 101]. 
SUMMARY
For many years, the clinical laboratory has been at the forefront 
of quality improvement activities in the healthcare sector. Its fo-
cus on analytical quality has resulted in an error rate of 4-5 sigma 
which surpasses most other areas in healthcare. However, 
greater appreciation of the prevalence of errors in the pre- and 
post-analytical phases and their potential for patient harm has 
led to increasing requirements for laboratories to take greater 
responsibility for activities outside their immediate control. Ac-
creditation bodies such as JCI and CAP specifically require 
healthcare organisations to have clear and effective procedures 
for patient/sample identification and communication of critical 
results and to monitor their performance in these areas. There 
are a variety of free on-line resources available to aid in manag-
ing the extra-analytical phase and the recent publication of 
quality indicators and proposed performance levels by the IFCC 
WG-LEPS provides useful benchmarking data for laboratories 
embarking on extra-analytical quality improvement programmes. 
Managing the extra-laboratory phase of the total testing cycle is 
the next challenge for laboratory medicine. By building on its 
existing quality management expertise, quantitative scientific 
background and familiarity with information technology, the 
clinical laboratory is well suited to play a greater role in reducing 
errors and improving patient safety.
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